Globus Medical, Inc. is the latest of the companies filing with the Securities and Exchange Commission to come public via an initial public offering.  No terms were projected yet but the company’s filing is for up to $100 million in common stock.  The company intends to apply to list its Class A common shares on the New York Stock Exchange under the stock ticker “GMED”.

There is a huge underwriting group for the size of this offering.  Underwriters include BofA Merrill Lynch, Goldman Sachs, Piper Jaffray, Leerink Swann, Canaccord Genuity, William Blair & Company, and Oppenheimer & Co.

Globus is a medical device company focused exclusively on the design, development and commercialization of products that promote healing in patients with spine disorders. It noted, “We are an engineering-driven company with a history of rapidly developing and commercializing products that assist surgeons in effectively treating their patients, respond to evolving surgeon needs and address new treatment options.”

The company claims to have launched over 100 products since its inception in 2003.  The company has also grown its sales from $15.6 million in 2004 to $331.5 million in 2011.  For the year ended December 31, 2011, Globus had $118.6 million in Adjusted EBITDA, representing an Adjusted EBITDA margin of 36%, and $60.8 million of net income.

While this company is not widely known by the public, it is refreshing to see an IPO filing from a medical technology player that has both growing revenues and profits.

FULL IPO FILING

JON C. OGG

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.